Influence of the Vitreomacular Interface on the Progression of the Diabetic Macular Edema After Anti-VEGF Injection
- Sponsor
- Fundació Institut Germans Trias i Pujol
- Study ID
- NCT02933905
- Status
- Completed
Conditions
- Anti-VEGF Treatment
- Diabetic Macular Edema
- Vitreomacular Interface
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 90 Years
- Healthy Volunteers
- Not accepted
Interventions
Study Details
Influence of the vitreomacular interface on the progression of diabetic macular edema after treatment with intravitreal injection of vascular endothelial growth factor inhibitors
Key Dates
- First listed
- Oct 14, 2016
- Start date
- Jan 31, 2014
- Status verified
- Oct 2016
- Primary completion
- Jan 31, 2015
- Completion
- Jun 30, 2016
Study Design
- Enrollment
- 38 participants (actual)
Arms
- Arm: Non-PVD subjectsPatients with no PVD on SD-OCT at basal visit
- Arm: PVD subjectsPatients with PVD on SD-OCT at basal visit
Primary Outcome Measure
Change in best-corrected visual acuity [ Time Frame: One year ]
Related Studies
- Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)PHASE1 · Recruiting · Ocugen · Deerfield Beach, Florida
- EC-104 Intravitreal Implant for the Treatment of Diabetic Macular EdemaPHASE1/PHASE2 · Recruiting · Eclipse Life Sciences, Inc. · Tampa, Florida
- Intranasal Delivery of Octreotide for Treatment of Diabetic Macular EdemaPHASE1 · Not Yet Recruiting · University of Alabama at Birmingham · Birmingham, Alabama
- Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)PHASE2 · Recruiting · Sierra Eye Associates · Reno, Nevada